… This study evaluated cardiovascular outcomes in patients with obesity. It was a large trial
conducted on 17,604 patients, accounting for the most patients included in this meta-analysis. …

… the impact of the GLP-1 analogue semaglutide on cardiovascular outcomes in people
with obesity without diabetes and renal outcomes in people with T2D and CKD, respectively. …

… with heart failure with preserved ejection fraction and obesity, but without type 2 diabetes,
that treatment with semaglutide led to larger reductions in heart failure–related symptoms and …

… elaborated potentially beneficial effects on cardiovascular … beyond weight reduction in obese
people without diabetes. … studies about semaglutide treating obesity without diabetes, one …

… an estimate of the pooled effect of semaglutide on BP in patients with obesity but without …
Cardiovascular outcome trials of GLP1-RAs in populations without diabetes are ongoing but …

… without diabetes. In the present study, we examined the effect of once-weekly semaglutide
2.4 mg on kidney outcomes … Large CVD outcome trials of GLP-1RAs in individuals with type 2 …

… placebo-controlled CV outcomes trial of semaglutide 2.4 mg once daily in people with
overweight or obesity without diabetes and with established CV disease. SELECT is the first …

… or CV outcomes in people with overweight/obesity without T2D. The effects of semaglutide
on … 3, a trial in people with overweight/obesity without T2D with a broadly similar design to …

… /m2, without diabetes, were randomized to sc semaglutide 2.4… : This analysis included 140
participants (semaglutide n=95; … was similar in those receiving semaglutide and placebo (total …

… Semaglutide is a glucagon-like peptide-1 (… 2 diabetes (oral semaglutide and subcutaneous
semaglutide) and for reducing the risk of cardiovascular events in people with type 2 diabetes …